Aspirin and Preeclampsia

• Status: Recruiting
• Trial end date: 2026-02-28
• Target enrollment: 0
• Participant gender: Female

Summary

This is a single-center, double-blind, randomized, placebo-controlled clinical trial. Peripartum and postpartum Activin A are significantly elevated in women with preeclampsia. Our hypothesis is that elevated Activin A levels reflect a remediable signal and that reducing postpartum Activin A levels with aspirin therapy will improve Global Longitudinal Strain (GLS) in preeclamptic patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Aspirin

Criteria

Inclusion Criteria:

1. Pregnant Adults between 18 and 45 years of age

2. Diagnosed with preeclampsia

3. Presenting for delivery with a singleton gestation.

Exclusion Criteria:

1. We will exclude patients in labor

2. Patients with preexisting cardiomyopathy, chronic hypertension, ischemic or valvular heart disease, pulmonary disease, diabetes mellitus, chronic kidney disease, multiple gestation

3. Plan to deliver outside of the participating site

4. Co-enrolled in other trials

5. Aspirin allergy

6. Clear indication for aspirin therapy or contraindication to aspirin therapy

7. Clinically significant conditions that might limit adherence to trial regimen (e.g., peptic ulcer disease, history of gastrointestinal bleeds, bleeding disorders)

8. Those who cannot provide consent